Author of

• 11794

  +

  P2.12 - Poster Session 2 - NSCLC Early Stage (ID 205)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11798

    +

    P2.12-004 - Percutaneous cryoablation for the treatment of inoperable stage I non-small cell lung cancer: mid-term outcome (ID 997)

    09:30 - 09:30  |  Author(s): H. Yashiro
    • Abstract

    Background
    To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer.

    Methods
    Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I primary lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable. Follow-up was based primarily on computed tomography.

    Results
    There were 22 patients with 34 carcinoma who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12 to 92 months, average 44±22 months, median 38 months. Local tumor progression was observed in two carcinomas (3%). Mean local disease progression-free interval was 88±8 months. Median local disease progression-free interval was not achieved. The overall 3-year survivals were 90.7%. Mean overall survival was 88±8 months. Median overall survival was not achieved. The disease-specific 3-year survivals were 100%. Mean overall survival was 81±14 months. Median overall survival was not achieved. The disease-free 3-year survivals were 77%. Mean disease-free survival was 64±19 months. Median disease-free survival was 89 month. Pulmonary function tests were done in 16 patients (18 treatments) before and more than 3 months after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively).

    Conclusion
    Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in inoperable stage I primary lung cancer patients.